Xtherapeutics ApS: Financial statements 2022
CVR: 37384089
Source: annual report 2022, Danish Business Authority
01/07/2021 – 30/06/2022
Xtherapeutics ApS (CVR 37384089) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -9,375 and a net result of DKK -14,381 compared with DKK -5,151 the year before. Equity in the 2022 report amounted to DKK 12,968. The solvency ratio was 63.3%.
- Gross Profit
- DKK -9,375
- Profit/Loss
- DKK -14,381
- Equity
- DKK 12,968
- Total Assets
- DKK 20,471
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -9 t. | -14 t. | 13 t. | - |
| 2021 | - | - | -5 t. | -13 t. | - |
| 2020 | 0 | 0 | 0 | 1 | - |
| 2019 | 0 | 0 | 0 | 1 | - |
| 2018 | - | - | -8 t. | -7 t. | - |
Official annual report
Keep an eye on Xtherapeutics ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringAbout Xtherapeutics ApS
Xtherapeutics ApS is a Danish company of the type Anpartsselskab based in Charlottenlund, founded in 2016. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Xtherapeutics IVS and Vaccex IVS. The management consists of Thomas Lars Andresen. The company is owned by Jonas Rosager Henriksen, Anders Elias Hansen and TLA-HOLDING 2010 ApS. In 2025, the company reported a gross profit of DKK 0 and a net result of DKK 0 compared with DKK -14,323 the year before. Equity in the 2025 report amounted to DKK -18,439.